Commonwealth Equity Services
LOGC

Commonwealth Equity Services’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Commonwealth Equity Services’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-11,199
Closed -$3K – 3797
2022
Q2 		$3K Sell
11,199
-1,709
-13% -$864 ﹤0.01% 3654
2022
Q1 		$8K Hold
12,908
– – ﹤0.01% 3690
2021
Q4 		$29K Buy
12,908
+72
+0.6% +$244 ﹤0.01% 3579
2021
Q3 		$58K Buy
+12,836
New +$56.5K ﹤0.01% 3487

Other funds holding LOGC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Commonwealth Equity Services's LOGC Position: Q3 2022 in Review

Commonwealth Equity Services sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q3 2022, closing a stake of 11,199 shares — an estimated $3K sold.

Commonwealth Equity Services first reported a position in LOGC in Q3 2021 and held it in 4 quarters. The position peaked at $58K in Q3 2021. 39 funds tracked by Wall St. Rank hold LOGC as of Q3 2022.

  • Commonwealth Equity Services reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Commonwealth Equity Services sold 11,199 LogicBio Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $3K.
  • Commonwealth Equity Services first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q3 2021 and held it in 4 quarters.
  • Commonwealth Equity Services's LogicBio Therapeutics, Inc. Common Stock position peaked at $58K in Q3 2021.
  • 39 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Commonwealth Equity Services's 13F filing for Q3 2022, filed 14 Nov 2022.